Employees using the One Drop digital diabetes management platform experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups.
Get the full story at our sister site, Drug Delivery Business News.
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space.
Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table.
The data showcased at ADA supported the usual continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology, plus different digital health platforms and diabetes reversal procedures.
BTIG analyst Marie Thibault wrote in a report that there was plenty of buzz on the ground at the event, particularly around Insulet’s Omnipod 5 AID system, Abbott’s recently FDA-cleared FreeStyle Libre 3 CGM and Bigfoot Biomedical’s Bigfoot Unity platform.
“In general, we believe that accuracy and clinical benefit is proven for all commercial CGM and AID offerings an…
New York-based One Drop presented new research about attitudes and adoption of continuous glucose monitors (CGMs) among people with type 2 diabetes at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.
Get the full story at our sister site, Drug Delivery Business News.
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.
From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.
Here are five of the biggest stories to come out of ATTD 2022:
Dexcom’s G7 is accurate in pediatric T1D patients
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.
The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.
Get the full story at our sister site, Drug Delivery Business News.
New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and statistically significant reductions in average blood glucose beyond six months and one year, reflecting meaningful reductions in estimated A1C.
Get the full story at our sister site, Drug Delivery Business News.
Major medtech companies vied for the biggest news splash at this year’s annual meeting of the American Diabetes Association, announcing promising results from studies of patients who used their latest diabetes technology.
The virtual 80th Annual American Diabetes Association Virtual Scientific Sessions, which runs through Tuesday, so far has featured news out of Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) and several smaller companies as well as studies showing how diabetes tech is helping diverse patient populations. More than 800 sessions have been planned.
Here are some of the highlights of this year’s conference, which began June 12.
Next>>